Added to YB: 2024-08-29
Pitch date: 2024-08-27
HROW [bullish]
Harrow, Inc.
+18.41%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
$1.9B
Pitch Price
$42.92
Price Target
N/A
Dividend
N/A
EV/EBITDA
42.87
P/E
-368.75
EV/Sales
8.18
Sector
Pharmaceuticals
Category
growth
Show full summary:
Harrow, Inc.: Blinded by the light
HROW: Strong H1 2024 growth across segments. Iheezo rebounding, Veyve promising, ImprimisRX +10% FY24. Triesence likely Q4. Revenue guidance >$180M, likely >$200M ex-Triesence. Expenses outpacing revenue growth (78% vs 40% YoY). Cash burn continues, but AR explains. Lofty valuation, but high growth and TAM potential.
Read full article (5 min)